SLC5A2 and type 2 diabetes mellitus: Similarly, other studies have shown that SGLT-2 inhibitors can reduce HbA1c in patients with T2DM by 0.11%–0.9% after a treatment cycle of not less than 6 months (Jabbour et al., 2014; Ridderstråle et al., 2014; Rodbard et al., 2019; Inzucchi et al., 2021).